• Find People
  • Campus Map
  • PiratePort
  • A-Z
    • About
    • Submit
    • Browse
    • Login
    View Item 
    •   ScholarShip Home
    • Division of Health Sciences
    • Brody School of Medicine
    • Microbiology and Immunology
    • View Item
    •   ScholarShip Home
    • Division of Health Sciences
    • Brody School of Medicine
    • Microbiology and Immunology
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of The ScholarShipCommunities & CollectionsDateAuthorsTitlesSubjectsTypeDate SubmittedThis CollectionDateAuthorsTitlesSubjectsTypeDate Submitted

    My Account

    Login

    Statistics

    View Google Analytics Statistics

    Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells

    Thumbnail
    View/ Open
    pone.0065569.PMC3680460.pdf (4.433Mb)

    Show full item record
    
    Author
    Cervello, Melchiorre; Bachvarov, Dimcho; Lampiasi, Nadia; Cusimano, Antonella; Azzolina, Antonina; McCubrey, James A.; Montalto, Giuseppe
    Abstract
    Molecular targeted therapy has shown promise as a treatment for advanced hepatocellular carcinoma (HCC). Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced HCC. However, although sorafenib is well tolerated, concern for its safety has been expressed. Celecoxib (Celebrex®) is a selective cyclooxygenase-2 (COX-2) inhibitor which exhibits antitumor effects in human HCC cells. The present study examined the interaction between celecoxib and sorafenib in two human liver tumor cell lines HepG2 and Huh7. Our data showed that each inhibitor alone reduced cell growth and the combination of celecoxib with sorafenib synergistically inhibited cell growth and increased apoptosis. To better understand the molecular mechanisms underlying the synergistic antitumor activity of the combination, we investigated the expression profile of the combination-treated liver cancer cell lines using microarray analysis. Combination treatment significantly altered expression levels of 1,986 and 2,483 transcripts in HepG2 and Huh7 cells, respectively. Genes functionally involved in cell death, signal transduction and regulation of transcription were predominantly up-regulated, while genes implicated in metabolism, cell-cycle control and DNA replication and repair were mainly down-regulated upon treatment. However, combination-treated HCC cell lines displayed specificity in the expression and activity of crucial factors involved in hepatocarcinogenesis. The altered expression of some of these genes was confirmed by semi-quantitative and quantitative RT-PCR and by Western blotting. Many novel genes emerged from our transcriptomic analyses, and further functional analyses may determine whether these genes can serve as potential molecular targets for more effective anti-HCC strategies.
    URI
    http://hdl.handle.net/10342/5701
    Date
    2013
    Citation:
    APA:
    Cervello, Melchiorre, & Bachvarov, Dimcho, & Lampiasi, Nadia, & Cusimano, Antonella, & Azzolina, Antonina, & McCubrey, James A., & Montalto, Giuseppe. (January 2013). Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells. PLoS ONE, (8:6), p.1-16. Retrieved from http://hdl.handle.net/10342/5701

    Display/Hide MLA, Chicago and APA citation formats.

    MLA:
    Cervello, Melchiorre, and Bachvarov, Dimcho, and Lampiasi, Nadia, and Cusimano, Antonella, and Azzolina, Antonina, and McCubrey, James A., and Montalto, Giuseppe. "Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells". PLoS ONE. 8:6. (1-16.), January 2013. April 20, 2021. http://hdl.handle.net/10342/5701.
    Chicago:
    Cervello, Melchiorre and Bachvarov, Dimcho and Lampiasi, Nadia and Cusimano, Antonella and Azzolina, Antonina and McCubrey, James A. and Montalto, Giuseppe, "Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells," PLoS ONE 8, no. 6 (January 2013), http://hdl.handle.net/10342/5701 (accessed April 20, 2021).
    AMA:
    Cervello, Melchiorre, Bachvarov, Dimcho, Lampiasi, Nadia, Cusimano, Antonella, Azzolina, Antonina, McCubrey, James A., Montalto, Giuseppe. Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells. PLoS ONE. January 2013; 8(6) 1-16. http://hdl.handle.net/10342/5701. Accessed April 20, 2021.
    Collections
    • Microbiology and Immunology

    xmlui.ArtifactBrowser.ItemViewer.elsevier_entitlement

    East Carolina University has created ScholarShip, a digital archive for the scholarly output of the ECU community.

    • About
    • Contact Us
    • Send Feedback